Mallinckrodt sells Intrathecal Therapy business in $203 million deal
Jan 30, 2017, 6:39am CST
Mallinckrodt president and CEO, said the deal is part of the company's effort to transform its portfolio by divesting non-core businesses and growing its platforms in autoimmune and rare diseases and hospital therapies.
http://www.bizjournals.com/stlouis/...intrathecal-therapybusiness-in.html?ana=yahoo
IMO - these guys don't appear to mess around...from my perspective they have timetable and a program.
Please DYOR ..fascinating times ahead.
Mallinckrodt, page-36
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |